Recursion Pharmaceuticals, Inc. RXRX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s accounts payable?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accounts payable of $20.35M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s accounts payable changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accounts payable decreased by 18.9% year-over-year, from $25.09M to $20.35M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s accounts payable?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s accounts payable has grown at a 49.1% compound annual growth rate (CAGR), from $15.47M to $76.45M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.